A Phase 4 interventional study of Sulfasalazine in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer. Terminated at 2 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2010, is the only one in phase 4, and was the 2nd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
Drug: Sulfasalazine
Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
Also known as: AZULFIDINE EN-tabs Tablets
Sulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin)
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Sulfasalazine Time for Cmax (Tmax) at Steady State
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Sulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Sulfapyridine Steady State Cmax and Cmin
Sulfapyridine and 5-aminosalicylic acid (5-ASA) are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Sulfapyridine Tmax at Steady State
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Sulfapyridine AUCtau at Steady State
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
5-aminosalicylic Acid (5-ASA) Steady State Cmax and Cmin
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
5-aminosalicylic Acid (5-ASA) Tmax at Steady State
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
5-aminosalicylic Acid (5-ASA) AUCtau at Steady State
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Screening through to and including 28 calendar days after the last administration of the investigational product
Number of Participants With Laboratory Test Abnormalities
Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes,clinical chemistry, and urinalysis (dipstick and microscopy).
Time frame: Screening, Day 0, and Day 7
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
Vital sign values which met categorical summarization criteria included: supine/sitting pulse rate less than (\<) 40 or more than (\>) 120 beats per minute (bpm); erect pulse rate \<40 or \>140 bpm; changes from baseline in same posture of systolic blood pressure (SBP) more than or equal to (\>=) 30 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>=20 mm Hg; SBP \<90 mm Hg; and DBP \<50 mm Hg.
Time frame: Screening, Day 0, and Day 7
The last participant enrolled in 2014 but the study was kept open for another 2 years and enrollment was not stopped. However, by 2016, no additional participants were enrolled and thus the study was closed. As such, the basic results for this study are only prepared in 2016 though last participant's last visit was in 2014.
| Milestone | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Started | 2 |
| Completed | 2 |
| Not completed | 0 |
| micrograms (mcg)/milliliter (mL) | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Cmax - Value 1 | 17.6 (4.51 to 17.6) |
| Cmax - Value 2 | 4.51 (0.988 to 4.28) |
| Cmin - Value 1 | 4.28 |
| Cmin - Value 2 | 0.988 |
| hours (hr) | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 2.02 |
| Value 2 | 5.92 |
| mcg*hr/mL | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 110 |
| Value 2 | 34.7 |
Sulfapyridine and 5-aminosalicylic acid (5-ASA) are primary metabolites of sulfasalazine, the study drug.
| mcg/mL | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Cmax - Value 1 | 21.7 |
| Cmax - Value 2 | 7.68 |
| Cmin - Value 1 | 14.7 |
| Cmin - Value 2 | 4.79 |
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
| hr | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 4.00 |
| Value 2 | 11.9 |
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
| mcg*hr/mL | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 232 |
| Value 2 | 67.3 |
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
| mcg/mL | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Cmax - Value 1 | 0.208 |
| Cmax - Value 2 | 0.0982 |
| Cmin - Value 1 | 0.0439 |
| Cmin - Value 2 | 0.0816 |
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
| hr | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 0.000 |
| Value 2 | 11.9 |
Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.
| mcg*hr/mL | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Value 1 | 1.63 |
| Value 2 | 1.04 |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| participants | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| TEAEs | 0 |
| SAEs | 0 |
| Withdrawals due to TEAEs | 0 |
Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes,clinical chemistry, and urinalysis (dipstick and microscopy).
| participants | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Number of Participants With Laboratory Test Abnormalities | 1 |
Vital sign values which met categorical summarization criteria included: supine/sitting pulse rate less than (\<) 40 or more than (\>) 120 beats per minute (bpm); erect pulse rate \<40 or \>140 bpm; changes from baseline in same posture of systolic blood pressure (SBP) more than or equal to (\>=) 30 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>=20 mm Hg; SBP \<90 mm Hg; and DBP \<50 mm Hg.
| participants | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria | 0 |
Collected over Screening through to and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sulfasalazine in Juvenile Idiopathic Arthritis | — | 0/2 (0%) | 0/2 (0%) |
The only 2 participants who were enrolled and completed the study at study termination were included in all analyses.
| Age, Continuous(years) | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Mean | 15.0 ± 1.4 |
| Gender(Participants) | Sulfasalazine in Juvenile Idiopathic Arthritis |
|---|---|
| Female | 1 |
| Male | 1 |
The record gives a start of Jun 2010, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulfasalazine